{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Nectar Lifescience Ltd
Nectar Lifescience Ltd Locks at Lower Circuit With 3.5% Loss — Sellers Queue, No Buyers in Sight
At Rs 11.00, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 16 Sep 2026, with unfilled sell orders and a frozen price.
Nectar Lifescience Ltd Locks at Upper Circuit With 2.43% Gain — Buyers Queue, Sellers Absent
At Rs 12.07, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 5% on 15 Sep 2026, with buyers queuing and no sellers willing to part with shares.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 13 September 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Nectar Lifescience Gains 17.31%: 2 Key Events Shaping the Week
Nectar Lifescience Ltd delivered a strong weekly performance, surging 17.31% from Rs.10.63 to Rs.12.47 between 24 and 28 August 2026, significantly outperforming the Sensex which marginally declined by 0.05% over the same period. The week was marked by a dramatic rally culminating in an upper circuit hit on 26 August, followed by a sharp reversal to the lower circuit on 28 August, reflecting heightened volatility and shifting investor sentiment in this micro-cap pharmaceutical stock.
Nectar Lifescience Ltd Locks at Lower Circuit With 4.43% Loss — Sellers Queue, No Buyers in Sight
At Rs 12.50, sellers were still queuing — but there were no buyers willing to take the other side. Nectar Lifescience Ltd locked at its lower circuit of 5% on 28 Aug 2026, with unfilled sell orders and a frozen price.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 August 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Nectar Lifescience Ltd Locks at Upper Circuit With 9.0% Gain — Buyers Queue, Sellers Absent
At Rs 12.46, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 9.0% on 26 Aug 2026, with buyers queuing and no sellers willing to part with shares.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 17 August 2026, providing investors with an up-to-date view of the company's performance and outlook.
Nectar Lifescience Ltd Locks at Upper Circuit With 5.0% Gain — Buyers Queue, Sellers Absent
At Rs 11.34, the buying was done — not because demand dried up, but because the exchange wouldn't let the stock go any higher. Nectar Lifescience Ltd locked at its upper circuit of 5.0% on 13 Aug 2026, with buyers queuing and no sellers willing to part with shares.
When is the next results date for Nectar Lifescience Ltd?
The next results date for Nectar Lifescience Ltd is 14 August 2026.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock’s current position as of 06 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 26 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 Jul 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 15 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 04 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 23 June 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.
Nectar Lifescience Declines 3.78% Amid Mounting Losses and Margin Pressures
Nectar Lifescience Ltd’s stock fell 3.78% over the week ending 5 June 2026, closing at Rs.11.96 compared to Rs.12.43 the previous Friday. This decline notably outpaced the Sensex’s modest 0.78% fall, reflecting investor concerns following the company’s quarterly results that revealed mounting operational losses and persistent margin pressures despite some balance sheet improvements.
Nectar Lifescience Ltd is Rated Strong Sell
Nectar Lifescience Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 08 July 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 11 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.
Nectar Lifescience Ltd Reports Flat Quarterly Performance Amidst Margin Pressures
Nectar Lifescience Ltd reported a flat financial performance for the quarter ended March 2026, marking a notable improvement from previous negative trends but still reflecting significant operational challenges. Despite a stabilisation in revenue growth, the company’s profitability metrics deteriorated sharply, underscoring persistent margin pressures in a competitive pharmaceutical sector.
Are Nectar Lifescience Ltd latest results good or bad?
Nectar Lifescience Ltd's latest results are concerning, showing a consolidated net loss of ₹67.92 crores and a significant decline in revenue, indicating severe operational challenges and a negative financial outlook. The company's persistent losses and lack of institutional confidence further highlight its precarious situation.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
